News
Public · Published
BillionToOne Q3 revenue rises 47%, raises 2026 outlook
BillionToOne reported third-quarter revenue growth of 47% year over year, driven by higher test volumes and prices. Net income and diluted earnings per share also increased sharply from a year earlier. It raised its 2026 revenue outlook to the headline's stated range and expects current profitability despite continued investment.
Published:
Updated:
What happened
BillionToOne reported third-quarter revenue growth of 47% year over year, driven by higher test volumes and prices. Net income and diluted earnings per share also increased sharply from a year earlier. It raised its 2026 revenue outlook to the headline’s stated range and expects current profitability despite continued investment.
Confirmed
Global impact / market context
Higher test volume and selling prices both contributed to revenue growth, while near-doubling oncology testing revenue points to a growing business line. If those drivers continue, they could support sales and help fund investment; maintaining profitability would indicate the company is balancing growth spending with costs.
Analyst inference
The company’s raised outlook gives investors a higher stated revenue range for 2026, but the article provides no share-price reaction to the results. It also reports a $125 median analyst price target and a $110.45 November 3 closing price, figures that describe expectations rather than assured returns.
Confirmed
What to watch
- Watch whether test volumes and average selling prices keep rising; the company attributed Q3 revenue growth to more tests delivered and a higher average price per test. Analyst inference
- Track progress against the raised 2026 revenue outlook and whether the company maintains current profitability while continuing investment, as it expects. Analyst inference
- Check whether oncology clinical testing revenue continues expanding after nearly doubling, and whether that segment’s growth contributes to continued overall revenue gains. Analyst inference
Evidence
- Original source link unavailable